Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

February 5, 2008

Primary Completion Date

August 3, 2010

Study Completion Date

July 17, 2014

Conditions
Carcinoma, Non Small Cell Lung
Interventions
DRUG

PF-00299804

Single arm (no comparator) study, oral once daily dosing, dose escalation (it is a phase 1/2 study) until disease progression, unacceptable toxicity or withdrawal of consent

Trial Locations (3)

110-744

Seoul National University Hospital, Department of Internal Medicine, Seoul

120-752

Severance Hospital, Yonsei University College of Medicine, Yonsei Cancer Center, Seoul

135-710

Samsung Medical Center, Department of Medicine, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY